Language:

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

European heart journal, 2022-10, Vol.43 (38), p.3618-3731 [Peer Reviewed Journal]

ISSN: 0195-668X ;ISSN: 1522-9645 ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehac237 ;PMID: 36017548

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Author: Humbert, Marc ; Kovacs, Gabor ; Hoeper, Marius M ; Badagliacca, Roberto ; Berger, Rolf M F ; Brida, Margarita ; Carlsen, Jørn ; Coats, Andrew J S ; Escribano-Subias, Pilar ; Ferrari, Pisana ; Ferreira, Diogenes S ; Ghofrani, Hossein Ardeschir ; Giannakoulas, George ; Kiely, David G ; Mayer, Eckhard ; Meszaros, Gergely ; Nagavci, Blin ; Olsson, Karen M ; Pepke-Zaba, Joanna ; Quint, Jennifer K ; Rådegran, Göran ; Simonneau, Gerald ; Sitbon, Olivier ; Tonia, Thomy ; Toshner, Mark ; Vachiery, Jean Luc ; Vonk Noordegraaf, Anton ; Delcroix, Marion ; Rosenkranz, Stephan
Subjects: abdominal radiography ; altitude ; ambrisentan ; amlodipine ; angioplasty ; anticoagulant therapy ; antiretrovirus agent ; aortic stenosis ; aortopulmonary shunt ; arterial gas ; assisted circulation ; Balloon pulmonary angioplasty ; beraprost ; beta adrenergic receptor blocking agent ; biochemical analysis ; birth control ; blood analysis ; BMPR2 gene ; bosentan ; bosutinib ; Cardiac and Cardiovascular Systems ; cardiopulmonary exercise test ; cardiovascular magnetic resonance ; chronic kidney failure ; chronic obstructive lung disease ; Chronic thrombo-embolic pulmonary hypertension ; chronic thromboembolic pulmonary hypertension ; clinical decision making ; Clinical Medicine ; comorbidity ; Congenital heart disease ; Connective tissue disease ; contraceptive behavior ; coronavirus disease 2019 ; cyclophosphamide ; dasatinib ; denervation ; digital subtraction angiography ; diltiazem ; dipeptidyl carboxypeptidase inhibitor ; disease association ; disease classification ; disease control ; disease course ; disease severity ; diuretic agent ; drug approval ; drug design ; drug potentiation ; drug safety ; dynamic contrast enhanced computed tomography ; early diagnosis ; echocardiography ; echography ; electrocardiogram ; endothelin receptor antagonist ; Endothelin Receptor Antagonists ; enkephalinase inhibitor ; Europe ; evidence based practice ; exercise ; felodipine ; fluid challenge test ; follow up ; gene ; genetic counseling ; genetic screening ; GRADE approach ; guanylate cyclase activator ; Guidelines ; health care facility ; health care management ; health care personnel ; heart arrhythmia ; heart catheterization ; heart failure with preserved ejection fraction ; heart failure with reduced ejection fraction ; heart left ventricle hypertrophy ; heart lung transplantation ; heart right ventricle failure ; hematologic disease ; hemoptysis ; human ; Human immunodeficiency virus infection ; Humans ; Hypertension, Pulmonary ; Hypertension, Pulmonary - diagnosis ; Hypertension, Pulmonary - therapy ; hypoxia ; iloprost ; immunology ; intensive care unit ; interferon ; interstitial lung disease ; iron deficiency anemia ; ivabradine ; Kardiologi ; Klinisk medicin ; Left heart disease ; liver transplantation ; lung artery pressure ; Lung disease ; lung embolism ; lung emphysema ; lung function test ; lung hemodynamics ; Lung transplantation ; macitentan ; mediastinitis ; Medical and Health Sciences ; Medicin och hälsovetenskap ; metabolic disorder ; methamphetamine ; microangiopathy ; mitomycin ; mitral valve disease ; mortality risk ; nifedipine ; noninvasive ventilation ; oxygen therapy ; pathophysiology ; patient compliance ; patient empowerment ; patient-reported outcome ; phase 3 clinical trial (topic) ; Phosphodiesterase type 5 inhibitors ; phosphodiesterase V inhibitor ; physical activity ; pneumococcal infection ; Pneumococcus vaccine ; ponatinib ; portal hypertension ; practice guideline ; pregnancy ; prognosis ; prostacyclin ; Prostacyclin analogues ; prostacyclin derivative ; Prostacyclin receptor agonists ; psychosocial care ; Pulmonary arterial hypertension ; pulmonary artery denervation ; pulmonary artery occlusion ; Pulmonary endarterectomy ; Pulmonary hypertension ; pulmonary tumour thrombotic microangiopathy ; rehabilitation care ; Review ; riociguat ; risk assessment ; risk factor ; SARS-CoV-2 vaccine ; schistosomiasis ; selexipag ; sildenafil ; sodium glucose cotransporter 2 inhibitor ; Soluble guanylate cyclase stimulators ; surgical technique ; systemic disease ; systemic sclerosis ; tadalafil ; telemonitoring ; terminal care ; thorax radiography ; thrombotic microangiopathy ; travel ; treprostinil ; tricuspid valve regurgitation ; vaccination ; vasoreactivity test ; ventilation-perfusion scan
Is Part Of: European heart journal, 2022-10, Vol.43 (38), p.3618-3731
Publisher: England
Language: English
Identifier: ISSN: 0195-668X
ISSN: 1522-9645
EISSN: 1522-9645
DOI: 10.1093/eurheartj/ehac237
PMID: 36017548
Source: GFMER Free Medical Journals
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

ISSN: 0195-668X ;ISSN: 1522-9645 ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehac237 ;PMID: 36017548

Searching Remote Databases, Please Wait